Novartis AG
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our divisions - Innovative Medicines and Sandoz - are supported by functional organizations with global scale. Innovative Medicines Made up of two business units, Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology & our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Novartis AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Sandoz AG
|
Slovene | 2.2 MB | |
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Novartis Pharma AG
|
Slovene | 4.4 MB | |
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža
|
Slovene | 2.4 KB | |
| 2019-10-22 08:00 |
Earnings Release
Novartis delivered another strong quarter with double digit sales growth and co…
|
English | 138.9 KB | |
| 2019-10-08 08:15 |
Regulatory News Service
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gai…
|
English | 28.9 KB | |
| 2019-10-02 08:15 |
Regulatory News Service
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing…
|
English | 21.0 KB | |
| 2019-09-29 17:30 |
Earnings Release
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3…
|
English | 25.3 KB | |
| 2019-09-17 08:15 |
Legal Proceedings Report
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
|
English | 24.4 KB | |
| 2019-08-30 08:15 |
Regulatory News Service
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-hea…
|
English | 24.4 KB | |
| 2019-07-29 08:00 |
Regulatory News Service
Novartis provides update on Phase III PARAGON-HF trial in heart failure patient…
|
English | 29.7 KB | |
| 2019-07-18 08:00 |
Earnings Release
Novartis delivers strong sales, double digit core operating income growth and l…
|
English | 137.7 KB | |
| 2019-07-01 18:30 |
M&A Activity
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic p…
|
English | 19.0 KB | |
| 2019-06-07 08:00 |
Board/Management Information
Novartis announces new leader of Pharmaceuticals Business Unit
|
English | 18.1 KB | |
| 2019-04-24 08:00 |
Earnings Release
Novartis starts 2019 with strong sales and double digit core1 operating income …
|
English | 95.6 KB | |
| 2019-03-27 00:35 |
Regulatory News Service
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to…
|
English | 27.7 KB |
Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Novartis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
NIPPON CHEMIPHAR CO., LTD. | Japan | 4539 | |
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |